Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

Data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span.  This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformin’s human physiologic and cellular effects that would be useful in identifying novel molecular targets.   


  • R01 Deadlines: Feb. 5, Jun. 5, Oct. 5
  • AIDS Deadlines: Jan. 7, May 7, Sep. 7

PA-18-025 Expiration Date May 8, 2020




Medical - Clinical Science
Medical - Translational

External Deadline

February 5, 2020